These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27327580)

  • 21. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG; Gupta AK; Cherman AM; Inniss KA
    J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of biologic agents in pediatric psoriasis.
    Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
    J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current investigational drugs in psoriasis.
    Ryan C; Abramson A; Patel M; Menter A
    Expert Opin Investig Drugs; 2012 Apr; 21(4):473-87. PubMed ID: 22400979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials.
    Langley RG; Reich K
    Br J Dermatol; 2013 Dec; 169(6):1198-206. PubMed ID: 23937204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
    Levine D; Strober BE
    Semin Cutan Med Surg; 2010 Mar; 29(1):28-34. PubMed ID: 20430305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).
    Chiricozzi A; Saraceno R; Novelli L; Fida M; Caso F; Scarpa R; Costa L; Perricone R; Romanelli M; Chimenti S; Chimenti MS
    Expert Opin Ther Pat; 2016 Jul; 26(7):757-66. PubMed ID: 27266423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologic therapy in erythrodermic and pustular psoriasis.
    Levin EC; Debbaneh M; Koo J; Liao W
    J Drugs Dermatol; 2014 Mar; 13(3):342-54. PubMed ID: 24595581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of new biological therapy in psoriasis treatment].
    Cortijo Cascajares S; García Rodríguez MP; Campo Angora M; Serrano Garrote O; Herreros de Tejada A
    Farm Hosp; 2004; 28(3):192-200. PubMed ID: 15222873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review.
    Semble AL; Davis SA; Feldman SR
    Am J Clin Dermatol; 2014 Feb; 15(1):37-43. PubMed ID: 24281790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center.
    Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
    Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
    Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new era in the management of psoriasis? The biologics: facts and controversies.
    Ferrándiz C; Carrascosa JM; Boada A
    Clin Dermatol; 2010; 28(1):81-7. PubMed ID: 20082956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging oral drugs for psoriasis.
    Mahmood T; Zaghi D; Menter A
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):209-20. PubMed ID: 25643592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature.
    Patel S; Patel T; Kerdel FA
    Int J Dermatol; 2016 May; 55(5):487-93. PubMed ID: 26711080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging topical treatments for psoriasis.
    Kivelevitch DN; Hebeler KR; Patel M; Menter A
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):523-32. PubMed ID: 24274614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological therapies for psoriasis.
    Mansouri B; Patel M; Menter A
    Expert Opin Biol Ther; 2013 Dec; 13(12):1715-30. PubMed ID: 24160990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.